Recent randomized controlled trials (RCTs) and meta-analyses of the RCTs reported that sodium–glucose cotransporter 2 (SGLT-2) inhibitors improved cardiovascular (CV) outcomes in patients with HF with reduced EF (HFrEF) [13], [14], [15], [16]. This evidence concerns the gene SLC5A2 and hydrops fetalis.